Pamela J. Cramer - 26 Jul 2025 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Signature
/s/ Stephen Vander Stoep, attorney-in-fact for Pamela J. Cramer
Issuer symbol
RYTM
Transactions as of
26 Jul 2025
Net transactions value
-$130,614
Form type
4
Filing time
29 Jul 2025, 18:56:28 UTC
Previous filing
11 Jul 2025
Next filing
12 Nov 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Cramer Pamela J. Chief Human Resources Officer C/O RHYTHM PHARMACEUTICALS, INC., 222 BERKELEY STREET, 12TH FLOOR, BOSTON /s/ Stephen Vander Stoep, attorney-in-fact for Pamela J. Cramer 29 Jul 2025 0001873517

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYTM Common Stock Options Exercise +3,125 +16% 22,334 26 Jul 2025 Direct F1
transaction RYTM Common Stock Sale $130,614 -1,520 -6.8% $85.93 20,814 29 Jul 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Restricted Stock Units Options Exercise $0 -3,125 -100% $0.000000 0 26 Jul 2025 Common Stock 3,125 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2 The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
F3 The restricted stock units vest as to 25% of the total shares on each of July 26, 2022, July 26, 2023, July 26, 2024 and July 26, 2025. The restricted stock units have no expiration date.